Compare Citius Pharmaceuticals Inc (CTXR) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Google Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Google Inc trades at $342.63 (market cap $4.20T). The key difference: Google Inc is far larger — about 209895.1× Citius Pharmaceuticals Inc's market cap, and Google Inc pays a 0.26% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GOOG | |
|---|---|---|
Market Cap | $20.01M | $4.20T |
Sector | Health | Technology |
52-Week High | $1.82 | $399.06 |
52-Week Low | $0.48 | $200.19 |
Enterprise Value | $16.23M | $4.09T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Alphabet (GOOG) trades at $342.71, down 3.69% on the day, with technical indicators showing a bearish trend near support at $340. The company reported strong fundamentals with Q2 2026 EPS of $9.11 beating expectations, revenue growth to $402.84B in 2025, and robust profitability margins. Recent news highlights AI advancements, including Gemini reaching 1 billion users, but also regulatory scrutiny from French media.
The stock presents a compelling long-term opportunity with a consensus price target of $431.67, representing 26% upside, supported by 87% analyst buy ratings. Risks include high capital expenditure forecasts up to $205B for 2026, competitive AI pressures, and ongoing regulatory challenges. Investors should weigh strong cash flow generation against aggressive investment cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
